<DOC>
	<DOC>NCT01128426</DOC>
	<brief_summary>The purpose of the study is to expand the understanding of the safety profile of 13vPnC in routine use following licensure and introduction of the vaccine.</brief_summary>
	<brief_title>Postlicensure Observational Safety Study of 13vPnC Administered to Infants and Toddlers</brief_title>
	<detailed_description />
	<mesh_term>Pneumococcal Infections</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Infants starting vaccination with 13vPnC in the first 6 months of life who are members of the Northern California Kaiser Permanente healthcase system and who receive at least 1 dose of 13vPnC during the study observation period will be included. Infants must not have had 7vPnC at the time of 13vPnC dose administration. Infants and children who were previously vaccinated with any number of doses of 7vPnC will be excluded.</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>3 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Pneumococcal conjugate vaccine</keyword>
</DOC>